ARR Leaderboard
Heidi is an AI medical scribe that drafts clinical notes from the consultation so doctors stop typing through appointments. Australian press reports a revenue surge putting it among the top AI scribes globally, Leonis Capital charts roughly twenty-six months from launch to $50M, and a $470M raise in 2026 valued it at $1.26B. The sourced numbers are below.
~$50M
Reported run rate, 2026
26 months
Launch to $50M, per Leonis
$470M
Funding, 2026
$1.26B
Valuation, 2026
Annualized run rate in USD millions. Heidi has not disclosed exact revenue; the curve follows Australian press reporting on its revenue surge and Leonis Capital's time-to-$50M tracking.
Launch → $50M ARR
~26 months
Leonis Capital
Funding, 2026
$470M
Forbes Australia
Valuation
$1.26B
Forbes Australia, 2026
Growth motion
Free clinician → clinic contracts
Company
2023
$0M ARR
Founded in Sydney by Dr Thomas Kelly, a practising doctor, after watching consultations lose their second half to keyboard work. — Company
2024
$8M ARR
Free tier for individual clinicians spreads the scribe doctor-by-doctor; word of mouth in medicine does the marketing. — Company / Estimated
2025
$25M ARR
Clinics and health systems buy team plans as scribe adoption moves from individual hack to standard practice. — Estimated
2026
$50M ARR
Revenue surge reported by AFR as Heidi rivals the top AI scribes; Leonis charts ~26 months to $50M; a $470M raise values it at $1.26B. — AFR / Forbes AU / Leonis
Latest reported run rate
~$50M
AFR / Leonis, 2026
Time to $50M
~26 months from launch
Leonis Capital
Funding, 2026
$470M
Forbes Australia
Valuation
$1.26B
Forbes Australia, 2026
Founder
Dr Thomas Kelly
Company
Founded
2023, Sydney
Company
Free tier
Individual clinicians
Company
Category
AI medical scribe
Company
Heidi's wedge is the individual clinician using it free — a doctor who stops typing through consultations becomes the internal advocate when the clinic standardizes. Conversion happens at the organization: team plans with shared templates, specialty-specific note formats and the compliance layer health systems require before any clinical tool is adopted.
The buyer economics are unusually clean: a scribe costs a fraction of a human medical scribe's salary while recovering consultation time, so clinic-level ROI is immediate and defensible in a procurement review. That dual motion — free product-led spread, paid enterprise conversion — is the engine behind the revenue surge AFR reported in 2026.
Revenue Mix
FAQ
Clink runs freemium-to-paid conversion, per-clinician seat billing and enterprise health-system invoicing with compliance-ready records for clinical AI.
Bill Clinical AI→